Patent 6998253 was granted and assigned to Genentech on February, 2006 by the United States Patent and Trademark Office.
Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.